Last reviewed · How we verify
Flore
Flore, developed by Arizona State University, is a marketed drug with a key composition patent expiring in 2028. The drug's market position and primary indication are not specified, but the patent expiry presents a significant milestone for potential generic competition. Without detailed revenue data or trial results, the primary risk is the loss of exclusivity and market share post-2028.
At a glance
| Generic name | Flore |
|---|---|
| Sponsor | Arizona State University |
| Modality | Biologic |
| Therapeutic area | Other |
| Phase | FDA-approved |
Approved indications
Common side effects
Key clinical trials
- Comparison of VER-01 to Opioids in Patients With Chronic Non-specific Low Back Pain (PHASE3)
- Probiotic Therapy for Children and Adults With Autism Spectrum Disorder (EARLY_PHASE1)
- Effect of Cannabinoids on Pain in Fabry Disease Patients (NA)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Flore CI brief — competitive landscape report
- Flore updates RSS · CI watch RSS
- Arizona State University portfolio CI